Last reviewed · How we verify
Rocuronium Bromide, Cisatracurium Besylate — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Rocuronium Bromide, Cisatracurium Besylate (Rocuronium Bromide, Cisatracurium Besylate) — NYU Langone Health.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rocuronium Bromide, Cisatracurium Besylate TARGET | Rocuronium Bromide, Cisatracurium Besylate | NYU Langone Health | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rocuronium Bromide, Cisatracurium Besylate CI watch — RSS
- Rocuronium Bromide, Cisatracurium Besylate CI watch — Atom
- Rocuronium Bromide, Cisatracurium Besylate CI watch — JSON
- Rocuronium Bromide, Cisatracurium Besylate alone — RSS
Cite this brief
Drug Landscape (2026). Rocuronium Bromide, Cisatracurium Besylate — Competitive Intelligence Brief. https://druglandscape.com/ci/rocuronium-bromide-cisatracurium-besylate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab